Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries (OP: SDZNY ) 46.04 +0.43 (+0.94%) Streaming Delayed Price Updated: 3:51 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about SDZNY Sandoz reports third-quarter and nine-month 2024 sales October 30, 2024 From Sandoz Group Via GlobeNewswire Sandoz US launches generic paclitaxel in single-dose vial, further expanding US oncology portfolio October 11, 2024 From Sandoz Group Via GlobeNewswire Psilocybin's Potentially Revolutionary Ability To Treat Depression Hinges On FDA Approval – AJNA BioSciences Is Standardizing Raw Materials To Meet Guidelines October 02, 2024 Psilocybin's Potentially Revolutionary Ability To Treat Depression Hinges On FDA Approval – AJNA BioSciences Is Standardizing Raw Materials To Meet Guidelines Via News Direct Exposures Product Safety UnitedHealth Follows Competitors, Replaces Humira with Lower-Cost Biosimilars September 11, 2024 UnitedHealth will remove AbbVie's Humira from its preferred drug lists by 2025, opting for lower-cost biosimilars like Amgen's Amjevita, in a move aimed at cutting prescription costs. Via Benzinga Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar position August 12, 2024 From Sandoz Group Via GlobeNewswire Sandoz reports second-quarter sales and half-year 2024 results August 08, 2024 From Sandoz Group Via GlobeNewswire Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases July 25, 2024 From Sandoz Group Via GlobeNewswire 3 Spinoff Stocks You Should Buy Now: July 2024 July 15, 2024 Spinoff stocks often take time to gain their footing in the market giving investors an opportunity to get in early. Via InvestorPlace Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem July 10, 2024 Drug prices continue to rise, driving up healthcare costs. Pharmaceutical companies usually hike drug prices at the beginning of each year. In January 2024 Via MarketBeat Upcoming Stock Spinoffs: Should You Pounce or Pass? July 04, 2024 Stock spinoffs are a unique opportunity to pick up unloved, unwanted businesses but patience is often needed before buying in. Via InvestorPlace FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US July 01, 2024 From Sandoz Group Via GlobeNewswire Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe May 22, 2024 From Sandoz Group Via GlobeNewswire Sandoz reports first quarter 2024 sales May 07, 2024 From Sandoz Group Via GlobeNewswire Sandoz Settles Patent Dispute With Amgen Related To Bone Disorder Drug Denosumab April 30, 2024 Sandoz resolves patent litigation with Amgen, paving the way for the launch of denosumab biosimilars Jubbonti and Wyost. Via Benzinga Topics Intellectual Property Exposures Intellectual Property Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG April 30, 2024 From Sandoz Group Via GlobeNewswire Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars April 30, 2024 From Sandoz Group Via GlobeNewswire Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering April 22, 2024 From Sandoz Group Via GlobeNewswire Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicines March 21, 2024 From Sandoz Group Via GlobeNewswire Sandoz reports fourth quarter 2023 sales and full-year 2023 results March 13, 2024 From Sandoz Group Via GlobeNewswire Sandoz receives FDA approval for first and only denosumab biosimilars March 05, 2024 From Sandoz Group Via GlobeNewswire Sandoz announces nominations to the Board of Directors and leadership change March 05, 2024 From Sandoz Group Via GlobeNewswire Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US market March 04, 2024 From Sandoz Group Via GlobeNewswire Generic/Biosimilar Player Sandoz Settles US Price Fixing Case For $265M February 29, 2024 Sandoz US, settles Generic Pharmaceuticals Pricing Antitrust Litigation for $265 million, addressing claims from direct purchasers without admitting wrongdoing. Post-approval, litigation continues with... Via Benzinga Sandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser class plaintiffs February 29, 2024 From Sandoz Group Via GlobeNewswire Why Is Cancer Immunotherapy Focused-Coherus BioSciences Stock Trading Higher Today? January 22, 2024 Coherus BioSciences agreed to sell its ophthalmology franchise for $170M to Sandoz. This aligns with CHRS' focus on oncology and will help reduce debt and overhead costs. Via Benzinga Venue Turmoil: Pharma Companies Oppose States' Bid to Relocate Price-Fixing Cases December 04, 2023 Major pharmaceutical firms, including generic manufacturers such as Teva Pharmaceutical Industries Limited (NYSE: TEVA), Sandoz Group (OTC: Via Benzinga Novartis Q3: Earnings Beat, Raised Operating Profit Outlook & More October 24, 2023 Novartis AG (NYSE: NVS) reported Via Benzinga Topics Earnings Exposures Financial Eli Lilly, McKesson, Novartis Flash Promising Chart Action October 09, 2023 Eli Lilly, McKesson, and Novartis are catching investors' attention with promising chart patterns and revenue growth, signaling potential buying opportunities. Via MarketBeat Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
